EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Treatment landscape, outcomes, and healthcare resource utilization in FLT3+ relapsed/refractory acute myeloid leukemia in Mexico

Andrés Gómez De León, Jamie Jung-Hee An, Georgia Gourgioti, Yanwen Xie, Jia Zhong, Eric Q Wu, Juan Guillermo Ariza, Li-Jen Cheng

Cancer Treatment and Research Communications · 2026

DOI: 10.1016/j.ctarc.2026.101229 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Treatment and Research Communications, 2026. Verfasst von Andrés Gómez De León und 7 weiteren Autor:innen. Beteiligte Einrichtung: Universidad Autónoma de Nuevo León, Facultad de Medicina y Hospital Universitario, Dr. José Eleuterio González, Monterrey, Mexico. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, fms-Like Tyrosine Kinase 3, Neoplasm Recurrence, Local, Patient Acceptance of Health Care. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Astellas Pharma Inc, Astellas Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: In Mexico, FMS-like tyrosine kinase 3 (FLT3) inhibitors have been approved for newly diagnosed or relapsed/refractory (R/R) FLT3-positive (FLT3+)acute myeloid leukemia (AML). This retrospective, physician panel-based chart review study evaluated the real-world treatment landscape, clinical outcomes, and healthcare resource utilization (HRU) in patients with FLT3+ R/R AML in Mexico. METHODS: This retrospective, non-interventional chart review utilized de-identified data from existing charts collected from 04/26/2022-07/18/2022. RESULTS: Of 165 patients, a phased treatment strategy (ie, an induction phase followed by consolidation and/or maintenance phase) was used in 63% of patients, with 7.3% undergoing hematopoietic stem cell transplantation (HSCT) in the first-line (1 L) setting. In the second-line (2 L) R/R setting, 18.2% received phased treatment and 4.2% underwent HSCT. Any type of complete remission (CR) was achieved in 78.1% of patients after 1 L induction; 75.8% relapsed, and 24.2% were refractory to 1 L. After 2 L induction, 79.2% of patients achieved any type of CR. Median overall survival and event-free survival were 21.7 and 13.6 months. Time to relapse after initial AML diagnosis was 13.7 months, and 10.9 months after HSCT at any line of treatment. Median time to HSCT after first diagnosis of R/R disease was not reached. HRU burden was high before and after diagnosis of R/R disease. CONCLUSION: This is the first multi-center study conducted in Mexico among patients with FLT3+ R/R AML. Despite high remission rates following 1 L induction therapy, patients experienced disease progression and HRU remained high, indicating an unmet need. Future studies are warranted to assess how outcomes evolve with novel treatments. GOV IDENTIFIER: Not applicable.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, Acutefms-Like Tyrosine Kinase 3Neoplasm Recurrence, LocalPatient Acceptance of Health CareHumansMexicoRetrospective StudiesFemaleMiddle AgedAdultMaleHematopoietic Stem Cell TransplantationAgedHealth ResourcesYoung AdultAdolescentDrug Resistance, Neoplasm

Stichwörter der Autor:innen

Acute myeloid leukemiaFLT3 mutationHealthcare resource utilizationHematopoietic stem cell transplantationRelapsed/refractory disease

Substanzen

fms-Like Tyrosine Kinase 3FLT3 protein, human

Autor:innen und Institutionen

  • Universidad Autónoma de Nuevo León, Facultad de Medicina y Hospital Universitario, Dr. José Eleuterio González, Monterrey, Mexico.
  • Astellas Pharma Singapore Pte Ltd., Singapore.
  • Astellas Pharma Europe Ltd., Addlestone, UK.
  • Analysis Group Inc., Los Angeles, CA, USA.
  • Analysis Group Inc., Boston, MA, USA.
  • Astellas Pharma Latam, Bogota, Colombia.

Förderung

  • Astellas Pharma Inc
  • Astellas Pharma

Zitieren

APA

De León, A. G., An, J. J., Gourgioti, G., Xie, Y., Zhong, J., Wu, E. Q., Ariza, J. G., & Cheng, L. J. (2026). Treatment landscape, outcomes, and healthcare resource utilization in FLT3+ relapsed/refractory acute myeloid leukemia in Mexico. Cancer Treatment and Research Communications. https://doi.org/10.1016/j.ctarc.2026.101229

Vancouver

De León AG, An JJ, Gourgioti G, Xie Y, Zhong J, Wu EQ, et al. Treatment landscape, outcomes, and healthcare resource utilization in FLT3+ relapsed/refractory acute myeloid leukemia in Mexico. Cancer Treatment and Research Communications. 2026. doi:10.1016/j.ctarc.2026.101229

BibTeX
@article{DeLen2026,
  author = {De León, Andrés Gómez and An, Jamie Jung-Hee and Gourgioti, Georgia and Xie, Yanwen and Zhong, Jia and Wu, Eric Q and Ariza, Juan Guillermo and Cheng, Li-Jen},
  title = {Treatment landscape, outcomes, and healthcare resource utilization in FLT3+ relapsed/refractory acute myeloid leukemia in Mexico},
  journal = {Cancer Treatment and Research Communications},
  year = {2026},
  doi = {10.1016/j.ctarc.2026.101229}
}
Kostenlos starten →